QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

Help viewing high resolution images Return to article

Fig. 2. Kra is expressed in the embryonic CNS. (A) Western blot analysis of S2 cell extracts using anti-Kra. The recognized protein is significantly depleted in kra RNAi-treated cells but not in gfp RNAi-treated control cells. (B-D) Whole-mount wild-type embryos stained with anti-Kra. Brackets mark the ventral nerve cord (VNC). (B) A stage 3 embryo. Lateral view. (C) A stage 13 embryo. Lateral view. (D) A stage 16 embryo. Ventral view. (E) A stage 16 embryo stained with preimmune serum. Ventral view. (F-H) A confocal section (1 µm) of a stage 16 wild-type embryo labeled with anti-Kra (F) and anti-Elav (G). (H) Merge of F and G. (I-K) A confocal section (1 µm) of a stage 16 wild-type embryo labeled with anti-Kra (I) and anti-Repo (J). (K) Merge of I and J. (I'-K') Higher magnification of the area marked with white broken lines in I-K. (L) The CNS of embryos, carrying both ap-GAL4 and UAS-HA-Kra^WT, stained with anti-HA. HA-Kra protein is detected in both the bodies (arrow) and the axons (arrowhead) of the Ap neurons. Scale bars: in F, 10 µm for F-L; in I', 10 µm for I'-K'.

Return to article